Michaela Liedtke
Co-Director, Stanford Amyloid Center · Stanford Health Care
Credentials: · · ·
History
- Present
Stanford Amyloid Center · Stanford Health Care
- Present
Stanford Adolescent and Young Adult Program · Stanford Health Care
- Present
Stanford · Stanford Health Care
- 2004–2005
Stanford University Medical Center (2005) CA
- 2002–2005
Stanford University Medical Center (2005) CA
1992–1996
Research
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine · 2019 · 1,419 citations
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
New England Journal of Medicine · 2016 · 1,107 citations
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
Leukemia · 2019 · 559 citations
24 papers
21 papers
20 papers
19 papers
17 papers
17 papers
17 papers
17 papers
Grants
- 2006–2012
Deregulation of Ras Signaling in MLL-Induced Leukemia
National Cancer Institute · K08
Contact PI · $690.5K · Stanford University
Clinical trials
- 2026–2028
A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement
Principal investigator · Not yet recruiting · Early phase 1
Stanford University
- 2013–2017
Principal investigator · Completed · Phase 2
Stanford University
- 2011–2017
Principal investigator · Completed · Phase 1, Phase 2
Michaela Liedtke
- 2010
Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM
Principal investigator · Completed · Phase 1
Stanford University